Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations

The statements, opinions, and data contained in articles published in this journal are solely those of the individual author(s) and contributor(s) and do not necessarily reflect the views of the journal, its editors, editorial board, owner, or Galenos Publishing House.

Neither the journal nor Galenos Publishing House endorses or recommends any commercial product, process, service, institution, or organization that may be mentioned or advertised in the journal. The publication of advertisements, product information, or links to external websites does not constitute endorsement or approval by the journal or the publisher.

The journal, its editors, editorial board, owner, and Galenos Publishing House make reasonable efforts to ensure the accuracy and integrity of published content; however, they cannot be held responsible for errors, omissions, or any consequences arising from the use of information contained in the journal, to the extent permitted by applicable law.

Information published in the journal is intended for scientific and educational purposes and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Readers should consult appropriately qualified healthcare professionals regarding individual medical conditions or treatment decisions.

External links are provided for informational convenience only. The journal and Galenos Publishing House are not responsible for the availability, accuracy, content, privacy practices, or policies of external websites.